findings have implications for the specificity of standalone clinical OCT assessments of stent healing.
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Translational Perspective
OCT is increasingly used to understand coronary stent coverage and healing, and inform mechanisms and risks regarding stent thrombosis. Here we demonstrate, via in vivo NIRF fibrin molecular imaging agent and catheter technology, that stent coverage by OCT may actually reflect coverage by fibrin, a prothrombotic material, particularly at the edges of drug-eluting stents. Translationally, an MRI version of the NIRF fibrin-imaging agent has already been tested in phase II trials, and nearinfrared fluorophores such as indocyanine green are clinically approved. From a catheter standpoint, clinical intracoronary testing of a NIRF-OCT catheter has already started. Therefore, NIRF-OCT fibrin imaging has a substantial translational potential and could help assess the healing of implanted coronary stents in preclinical and clinical use.
INTRODUCTION
Stent thrombosis is a life-threatening complication of coronary artery stents that occurs when a blood clot forms acutely within a stent. Patients remain at risk of stent thrombosis from both bare metal stents (BMS) and drug-eluting stents (DES), despite dual antiplatelet therapy (DAPT) 1 . Seminal pathology studies have revealed that stents with delayed healing, characterized by incomplete endothelialization and pro-thrombotic fibrin deposition, are at heightened risk of stent thrombosis 2, 3 .
Furthermore, a recent landmark clinical study shows that the risk of stent thrombosis persists for years, and is reduced, but not eliminated, by prolonged DAPT 4 .
Therefore the questions of which subjects remain at risk for stent thrombosis, and which subjects can safely stop DAPT, remain of paramount importance.
Assessment of stent endothelialization and fibrin deposition has historically been performed at autopsy 2, 3 . Recently however, investigators have applied highresolution optical coherence tomography (OCT) to assess tissue overlying stent struts, termed "OCT strut coverage", as a surrogate for coronary stent healing, and to potentially inform the risk of stent thrombosis. However, limitations of OCT including insufficient resolution and a lack of fibrin-specific tissue contrast 5, 6 might limit the ability of OCT to accurately identify healed stents and to predict clinical stent thrombosis. These limitations might underlie the unclear association between measures of OCT strut coverage and subsequent clinical events. Therefore, a strategy to rapidly, comprehensively, and quantitatively assess fibrin deposition on coronary stents in vivo, in combination with simultaneous tissue coverage assessment by OCT, could significantly advance our knowledge regarding stent healing, and potentially improve the prediction of stent thrombosis.
Molecular imaging offers the potential to detect fibrin at high-resolution using intravascular near-infrared fluorescence (NIRF)-OCT imaging in vivo. This concept was recently introduced in a single timepoint study that imaged stents that were soaked ex vivo with high concentrations of NIR fluorescent plasma, and then implanted in rabbit arteries and immediately imaged 7 . This preliminary concept however was not informative for clinically translatable imaging, as it (1) did not demonstrate that an intravenously injectable fibrin-targeted agent could stably bind implanted stents under conditions of arterial blood flow; (2) did not assess whether physiological levels of fibrin following stent implantation could be detected in vivo, especially in subacutely placed stents with lower fibrin levels; and (3) utilized a nanomaterial imaging agent with limited translatability 8 .
In this translational study, we harnessed intravascular NIRF-OCT fibrin molecular-structural imaging to identify the healing status of implanted DES and BMS, compared to standalone OCT-tissue coverage assessment, and further utilized serial NIRF-OCT to assess fibrin persistence over time in single stents in vivo.
METHODS

The Institutional Animal Use and Care Committee at Massachusetts General
Hospital approved all animal studies (#2004P001401). Discarded human blood products were obtained using a Partners institutional review board-approved protocol (#2013N000015). Full details are described in the Online Supplement.
Coronary stent implantation in rabbits
Coronary BMS (ML VISION, 3.5x12 mm, Abbott Vascular) or everolimuseluting DES (XIENCE V, 3.5x12 mm, Abbott Vascular) were implanted into the infrarenal aorta in New Zealand white rabbits, which is the same caliber as a human coronary artery. The orientation of BMS and DES (proximal or distal segments of the abdominal aorta) was chosen randomly.
Intravascular NIRF-OCT molecular-structural imaging in vivo
The intravascular NIRF-OCT imaging system and catheter have been previously described 
Statistical Analysis
Results are expressed as mean±SD. A value of P<0.05 was considered statistically significant for two and multiple groups comparison. Two-sided p-values are reported. For multiple testing, adjusted p-values are reported.
RESULTS
Synthesis, binding, and blood half-life of the fibrin-targeted NIRF agent FTP11-
CyAm7
We recently developed a fibrin-targeted NIRF imaging agent (FTP11-Cy7) and validated it in murine thrombosis 10 . For the scale-up synthesis to image fibrin in rabbit, we conjugated an in-house NIR fluorophore (CyAm7, ex/em 744/769 nm) to a validated fibrin-binding peptide 10, 11 (Supplemental Figure 3A) . In vitro, FTP11-CyAm7 enhanced fibrin-rich clots from both rabbit and human plasma, significantly above free CyAm7 control (TBR= 20.5±3.5 vs. 3.4±1.4 for rabbit clots, 25.1±5.2 vs.
2.1±0.2 for human clots, p<0.0001 respectively, Supplemental Figure 3B ). The blood half-life of FTP11-CyAm7 was 8.1 minutes in rabbits (95% CI, 6.5-10.9, Supplemental Figure 3C ).
In vivo NIRF-OCT of fibrin deposition on coronary stent struts
A total of 20 stents (n=13 BMS, n=7 DES) were implanted and 28 NIRF-OCT imaging pullbacks of coronary stents (17 BMS, 11 DES) including serial imaging were analyzed (Supplemental Figure 1) . Intravascular NIRF-OCT imaging was performed prior to and then two hours after intravenous injection of FTP11-CyAm7.
Minimal background NIRF signal was observed prior to FTP11-CyAm7 injection (data not shown), consistent with low autofluorescence in the NIR window 12 . In contrast, the post-injection images revealed elevated NIRF signal surrounding stent struts ( Figure 1 ). Higher NIRF fibrin signal was evident at stent edges. Axial NIRF-OCT fusion images demonstrated fibrin deposition on and around stent struts ( Figure   1A -B).
Fluorescence microscopy of longitudinally opened stents confirmed similar localization of NIRF-fibrin signal within the stent ( Figure 1A ). Histological evaluation demonstrated that the FTP11-CyAm7 signal colocalized with fibrin deposition identified by Carstairs' stain and fibrin immunostaining ( Figure 1C-D) . NIRF fibrin signal localized specifically near stent struts, extending prior findings of fibrin deposition patterns in a flow loop model 13 and histopathological studies 2, 3, 14, 15 . These results indicate that NIRF-OCT fibrin molecular imaging can accurately assess fibrin deposition in stents in vivo.
OCT assessment of tissue coverage on coronary stent struts in vivo
The OCT per strut analyses of coverage and malapposition are summarized and shown in Table 1 . OCT revealed that DES exhibited greater rates of uncovered stent struts compared to BMS at both day 7 (p<0.001) and day 28 (p<0.05), consistent with prior studies 2, 3, [14] [15] [16] .
BMS fibrin dissipates from day 7 to day 28, as assessed by NIRF-OCT molecular-structural imaging
To assess the temporal dynamics of fibrin deposition on BMS in vivo, we next imaged BMS of two different healing stages (day 7 and day 28) implanted in the infrarenal aorta of rabbits (N=3). We selected the d7 and d28 time points in rabbits to correspond to human timepoints for stent healing at 1 month (subacute) and 6 months (late), respectively 16, 17 . In vivo NIRF-OCT molecular imaging of fibrin in day 7
BMS showed elevated NIRF signal, primarily at the stent edges. In contrast, little NIRF fibrin signal was observed in day 28 BMS (p<0.0001, Supplemental Figure 4 ).
Greater fibrin deposition is evident in DES compared to BMS at day 7 in vivo
It remains unclear whether there are differences in the subacute stent thrombosis rates between BMS and DES. We compared the fibrin deposition between BMS and DES 7 days after implantation (n=7 BMS, n=7 DES), where day 7
in the rabbit corresponds to 1 month in humans 16 . We observed significantly greater NIRF fibrin signal in DES than BMS at day 7 after stent implantation (p<0.0001, Figure 2 ). DES at day 7 also demonstrated an edge-enhanced NIRF distribution pattern similar to BMS, but greater in magnitude. In addition, we also observed relatively higher NIRF fibrin signal throughout the mid stent segment in DES compared to BMS ( Figure 2I ).
Comparison of fibrin dissipation rates in BMS and DES in vivo
The rate of fibrin dissipation in coronary stents in vivo is unknown. To assess temporal changes in fibrin deposition in individual BMS and DES in vivo, a subset of rabbits (N=4) underwent serial NIRF-OCT fibrin imaging at d7 and then again at d28 post-stent implantation. We first confirmed that at d28, minimal residual NIRF signal was remnant from the initial d7 FTP11-CyAm7 injection (Supplemental Figure 5 ).
Co-registration of serially obtained d7 and d28 NIRF-OCT datasets revealed that both BMS and DES showed reductions in fibrin-NIRF signal ( Figure 3A -B). Day 28 DES exhibited quantitatively greater fibrin deposition at all zones of the stent (edges, mid section) compared to matched d28 BMS (p<0.0001, Figure 3C ). En face whole mount fluorescence microscopy corroborated higher fibrin-NIRF signal in d28 DES (Supplemental Figure 6 ). Furthermore, en face microscopy of DAPI-stained tissue revealed less cellularity in d28 DES versus d28 BMS. Carstairs' fibrin staining also confirmed sustained peri-strut fibrin deposition (Supplemental Figure 6C- . Although strut coverage was highest at the stent edges as previously reported 14 , the NIRF fibrin signal was also highest at the stent edges (outer 2 mm). Therefore, we analyzed the extent of fibrinrich neointima at day 7 and 28 at the stent edges (n=8 for d7 stents, n=8 for d28 stents). Interestingly, most OCT-covered tissue on day 7 DES struts was fibrin-rich (92.8±9.5% of edge struts), and significantly higher than day 7 BMS (fibrin-positive struts 55.8±23.6%, p=0.0017).
At d28, fibrin on DES edge struts was 3-fold more prevalent than on BMS (18.6±10.6% of DES vs. 5.1±8.7% of BMS, p=0.0156, Figure 4A ). These findings were supported by histological analyses ( Figure 4D ). The functional endothelial cell marker eNOS was well-expressed in areas of BMS neointima, in contrast to DES neointima, consistent with prior studies 15 .
OCT grayscale signal intensity and NIRF-fibrin relationships
While differences in OCT grayscale signal intensity (GSI) of stent strut tissue coverage might distinguish fibrin 18 , we found that the OCT GSI was similar between d7 BMS and DES (BMS 0.50±0.11 vs. DES 0.51±0.08, p>0.99), and between d28 BMS and DES (0.59±0.07 vs. 0.58±0.07, p>0.99, Figure 4C ), despite higher NIRFfibrin in DES>BMS at each time point. Significantly higher GSI was observed in d28 mature neointima compared to d7 immature neointima (p<0.0001 for BMS and p=0.0011 for DES, Figure 4C ), consistent with prior studies 17, 18 .
Quantitative assessment of NIRF-fibrin and OCT coverage relationships in BMS and DES healing
NIRF-fibrin and OCT-coverage stent strut data of d7 and d28 BMS and DES at edges were analyzed and further classified into one of four groups: NIRF-fibrin negative and OCT-covered, identifying healed stent struts; or NIRF-fibrin positive,
OCT-uncovered; NIRF-fibrin positive, OCT-covered; or NIRF-fibrin negative, OCTuncovered; these latter three groups identifying unhealed stent struts. The data presented in Figure 6 demonstrates that in subacute and late time points after stent implantation, a significant percentage of OCT-covered stent struts are NIRF fibrinpositive and thus can be considered to be unhealed ( Figure 5 , yellow groups). In addition, the proportion of unhealed stent struts remained significantly higher in DES compared to BMS at both d7 (p<0.001) and d28 (p<0.05).
DISCUSSION
A key finding of this study is that a significant portion of OCT-covered stent struts may be actually covered by fibrin and are therefore unhealed, particularly earlier on after stenting. Specifically, over 90% of OCT-covered edge DES struts at day 7, corresponding to the 1 month timepoint in humans, were positive for fibrin, a pro-thrombotic interface that mediates stent thrombosis [1] [2] [3] . At day 28, corresponding to the 6-12 month timepoint in humans, combined NIRF-OCT determined that 23%
of DES edge stents struts were unhealed-4 times the percentage identified by standalone OCT ( Figure 5A ). The overall results demonstrate that intravascular NIRF fibrin molecular imaging can improve the identification of unhealed clinical coronary stents by clarifying whether OCT tissue coverage represents fibrin in vivo.
OCT is a promising approach to identify unhealed stents lacking tissue coverage, however, standalone OCT does not accurately distinguish between stent coverage by endothelium/smooth muscle cells (physiological stent healing) from coverage by prothrombotic fibrin, which indicates an unhealed stent 6 . We observed a substantial proportion of OCT-covered stent struts are actually covered by fibrin ( Figure 5 ). Therefore a subset of OCT-covered stent struts is actually unhealed, rather than healed. These in vivo findings extend the ex vivo study by Nakano et al.
that demonstrated standalone OCT misclassification of healed stents occurs due to coverage by fibrin and inflammatory cells 6 . Moreover, the observed mismatches between OCT and NIRF fibrin imaging fundamentally changes the perspective on whether such an OCT-covered stent could be prone to stent thrombosis. This finding is of substantial importance for ongoing clinical standalone OCT-based trials -which are predicated on the concept that tissue coverage of a stent means that a stent is healed and carries a low risk of stent thrombosis. The NIRF findings herein demonstrate that caution may be needed in interpreting the healing state of stents by standalone OCT, particularly in the subacute post-implantation period where unhealed stents are more prevalent.
While OCT grayscale intensity differences might identify fibrin 18 , grayscale intensity was similar between DES and BMS in our study, despite DES having significantly higher fibrin content than BMS, further strengthening the value of NIRF molecular imaging to identify fibrin-rich unhealed stent struts. In addition, OCT stent strut coverage analysis is highly time-consuming (hours per individual stent), limiting its application in point-of-care analysis 19 . In contrast, 2D NIRF fibrin maps (e.g. Figure 1A ) readily display fibrin-rich areas on stents. By specifically and rapidly assessing fibrin deposition on stents in vivo, NIRF molecular imaging powerfully complements standalone OCT structural imaging.
Pathophysiologically, NIRF-OCT fibrin-structural imaging provided new insights into differences in DES and BMS healing. Serial NIRF-OCT at subacute timepoints demonstrated that DES exhibited higher fibrin persistence than BMS out to day 28 in rabbits, consistent with prior histopathological data. 15 These findings need to be taken into context with studies of acute thrombus formation. We and others have shown, using these very same stents, that the coatings associated with DES are not inherently thrombogenic when evaluated in the acute setting associated with implantation and before drug release. 13 This still remains the case. What we now show is that as DES elute their drug, there is a signal of increased subacute fibrin deposition that diminishes over time. Collectively these data reinforce three timeperiods where implanted stents may be susceptible to thrombosis: an acute period related to surface effects and strut dimensions; a subacute period related to concentration of drug in local vicinities; and a third period related to a stunted or incomplete vascular healing response.
Although extrapolating healing rates from rabbits to humans is approximate, prior reports demonstrate that vascular healing in rabbits occurs 5-6 times faster than humans, and propose that day 7 and day 28 in rabbits correspond to 1 month and 6-12 months in humans, respectively 16 . While current clinical guidelines indicate that 6-12 months of DAPT may be sufficient for prevention of DES thrombosis 20 , the recent DAPT study suggests that extended anti-platelet therapy of 30 months is beneficial 4 . Therefore, the optimal duration of DAPT for coronary stents still remains unknown. Accordingly, the accurate identification of unhealed coronary stents could offer substantial value in guiding the duration of DAPT.
Clinical Translation
The current study significantly advances the potential for intracoronary molecular imaging of fibrin deposition on stents. While an earlier study described the feasibility of imaging fluorescently-coated clots placed on stents ex vivo 7 , the present study provides the first demonstration that stent fibrin deposition can be imaged in vivo using an injectable NIRF molecular imaging agent, FTP11-CyAm7. As an MRI version of FTP11-CyAm7 has already been tested in phase II trials 11 , and NIR fluorophores such as indocyanine green are clinically approved, the fibrin NIRF molecular imaging agent has substantial translational potential. From a catheter standpoint, clinical intracoronary testing of a NIRF-OCT catheter has already been initiated 21 . These encouraging developments suggest that clinical NIRF molecular imaging of fibrin deposition on stents may be feasible in the near future.
Stent thrombosis remains a highly morbid, persistent complication of BMS and DES, and while despite long term DAPT reduces stent thrombosis, thrombosis risk remains, and moreover appears to increase quickly after cessation of DAPT 1, 4 .
The ability to image fibrin deposition on stents could therefore have several important applications. First, identifying fibrin-bearing stents might better predict the risk of stent thrombosis, motivating a re-review of optimal DAPT choices and duration, and selection for novel stent healing approaches. Second, fibrin imaging might prove to be a valuable surrogate endpoint for clinical trials evaluating new prohealing stents and pharmacotherapies designed to reduce stent thrombosis.
Study limitations
As with other studies of rabbit stent healing 15 , coronary stents were implanted into the normal aorta in rabbits without atherosclerotic plaque or curvature, as opposed to human coronary arteries. Iliac arteries, generally used in preclinical stent healing studies 15 were not stented due to limited repeated vascular access from femoral arteries, and to allow direct comparison between two stents within one pullback. While determining the precise mechanisms underlying enhanced fibrin deposition at the stent edges is beyond the scope of this manuscript, future studies will utilize computational fluid dynamic models 22 to explore this issue. As light cannot penetrate through metallic stent struts, NIR fluorophores beneath metallic stent struts will not be detected by intravascular fluorescence reflectance imaging.
Lastly, delayed healing is only one feature underlying stent thrombosis, and other factors such as blood thrombogenicity and neoatherosclerosis will need to be integrated with NIRF-OCT fibrin imaging.
Conclusions
Intravascular NIRF fibrin molecular imaging improves the detection of unhealed stents by specifically determining whether OCT tissue coverage reflects fibrin deposition. Compared to NIRF-OCT, standalone OCT over-classifies stents as healed, even at subacute timepoints after stent implantation. Intravascular fibrin NIRF-OCT may ultimately help better identify stents at risk for stent thrombosis.
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SUPPLEMENTAL MATERIAL Supplemental Methods
Synthesis of fibrin-targeted NIRF peptide molecular imaging agent (FTP11-CyAm7.
All chemicals and solvents were purchased from Fisher Scientific or Sigma Aldrich, and used as received without further purification. Gradients were run with buffer A (H 2 O/0.1% TFA) and buffer B (90% acetonitrile/10% H 2 O/0.1% TFA). Electrospray mass spectrometry was accomplished on a Micromass ZQ4000. For analytical HPLC a C-18 reverse phase column (Agilent Pursuit XRS 10 µm) with dimensions of 250 mm × 4.6 mm was used at a flow rate of 1.0 ml/min. For semipreparative HPLC a C-18 reverse phase column (Agilent Pursuit XRS 10 µm) with dimensions of 250 mm × 21.2 mm was used with a flow rate of 21.0 ml/min.
The FTP11 peptide was prepared as previously described 1 and received from the Massachusetts General Hospital Peptide/Protein Core Facility completely protected except for the N-terminus. The succinimidyl ester of CyAm7 was a gift from the Chemistry Core at the Center for Systems Biology at the Massachusetts General Hospital. To 434 mg of the resin (1.1 x 10 -4 mol) in 5 mL DMF was added Fmoc-Namido-dPEG 6 -acid (262 mg, 4 equiv, Quanta Biodesign, Plain City, OH), (benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyBOP, 237 mg, 4 equiv) and triethylamine (64 µL, 4 equiv). The reaction proceeded for 16 h, at which time the resin was washed thrice with DMF, and thrice with methanol. The terminal fluorenylmethyloxycarbonyl protecting group was removed by thrice suspending the resin in a 20% piperidine solution in DMF (5 mL) for 20 min while nutating, followed by washing twice with DMF. After the terminal deprotection reaction, the resin was also washed twice with methanol. The resin (100 mg, 2.6 x 10 -5 ) was subsequently suspended in 3 mL DMF to which the succinimidyl ester of CyAm7 (58 mg, 2 equiv), and triethylamine (7.3 µL, 2 equiv) were added. The reaction was allowed to proceed for 72 h, at which time it was washed thrice with DMF, and twice with methanol to give a dark black resin. The peptide was cleaved from the resin using reagent K (3 mL, TFA/thioanisole/water/phenol/ethanedithiol, 82.5:5:5:5:2.5 v/v) for 2 h, filtered to remove the resin, and precipitated with 10 mL methyl tert-butyl ether (MTBE). The green precipitate was washed a further 2 times with MTBE and dried under vacuum. The precipitate was subsequently dissolved in 1 L of buffer A containing 0.6 equiv of 4,4'-dipyridyl disulfide (4-PDS), and the cyclization reaction was monitored my ESI-MS (positive mode). Once the reaction stalled, an additional 0.6 equivalents of 4-PDS was added. After reaction completion, the product was loaded onto a C-18 cartridge (Waters Sep-Pak Vac, 35 cc, C18-10g) equilibrated with Buffer A, and eluted with 10 column volumes of buffer A, followed by 10 column volumes of 95:5 buffer A:B, followed by methanol to remove the blue-green product. The fractions containing the product were evaporated to dryness, dissolved in 4 mL of a mixture of Buffers A and B (50/50) and purified by HPLC (gradient from 100% buffer A to 0% buffer A over 30 min, 700 nm collection trigger, 21 mL/min), eluting at 14.9 min. The final product, FTP11-CyAm7, was recovered via lyophilization.
In vitro assessment of FTP11-CyAm7 binding to fibrin-rich clots
Binding of FTP11-CyAm7 to human and rabbit plasma clots was examined in vitro as previously outlined 1 . Briefly, fibrin-rich plasma clots were generated with human fresh frozen plasma (FFP) and rabbit FFP by treating with thrombin and CaCl 2 . FTP11-CyAm7, unconjugated free-CyAm7 (200 pmol/well), or PBS were added to clots and incubated for 30 minutes at 37°C. After washing with PBS, NIRF intensity was quantified by fluorescence reflectance imaging (FRI). Human FFP was obtained using an institutional review board-approved human subject protocol to use discarded human blood products. Rabbit plasma was obtained by blood drawing from healthy rabbits as part of an MGH IACUC-approved protocol.
Blood half-life study of FTP11-CyAm7
To determine the blood half-life of FTP11-CyAm7 in rabbits, serial blood sampling was performed. Rabbits (n=4) received a 50 nmol/kg iv injection of FTP11-CyAm7 dissolved in PBS. At sequential timepoints, a 100 μL volume of blood was obtained and mixed with 100 μL of heparin (1000 USP units/ml), and kept on ice until analysis. The NIR fluorescence of the blood at each time point was quantified by FRI 1 . The signals were then normalized to the NIRF signal at one minute post-injection. Exponential fitting yielded the blood half-life of FTP11-CyAm7 (GraphPad Prism 5.0, San Diego, CA).
Coronary stent implantation into the rabbit aorta
The in vivo studies are outlined in Supplemental Figure 1 . New Zealand white rabbits (n=12, 3.0-3.5 kg, Millbrook Farms, Amherst, MA) were anesthetized with intramuscular ketamine (35 mg/kg)/xylazine (5mg/kg) mixture and maintained by inhaled isoflurane (1%-5% vol/vol, Baxter, Deerfield, IL). A 4F introducer was inserted into the left iliac artery using fluoroscopic guidance. Intra-arterial heparin (150 units/kg) and nitroglycerin (50 ug) were administered. A baseline angiogram using an intra-arterial injection of iodinated contrast agent (Ultravist, Bayer HealthCare) was then performed. A 0.014 inch guidewire was next introduced into the abdominal aorta. Under fluoroscopic guidance, infra-renal aorta was then stented with a bare metal stent (BMS, ML VISION, 3.5 mm diameter x 12 mm length, Abbott Vascular) or an everolimus eluting stent (EES, XIENCE V, 3.5 mm x 12mm, Abbott Vascular), and stent deployment was performed to achieve a visual target stent-to-artery ratio of approximately 1.1-1.2:1 2, 3 . The orientation of BMS and DES (proximal or distal segments of the abdominal aorta) was chosen randomly. Rabbits received daily oral aspirin (40mg) from one day before stenting until sacrifice 4, 5 . For comparing day 7 and day 28 BMS in the same rabbit, we implanted the first BMS at 28 days before imaging, followed by implantation of the second BMS 7 days before imaging (Supplemental Figure 1) . A total of 24 stents (BMS=16 and DES=8) were implanted in 12 rabbits. Sample sizes were chosen in accordance based on a consensus document for preclinical interventional device evaluation 3 . Three stents (BMS=2 and DES=1, n=2 rabbits) were dislodged before imaging and excluded from analyses. No rabbits died during study procedures or prior to endpoint determination.
Intravascular NIRF-OCT imaging system
The intravascular NIRF-OCT imaging system and catheter have been described 6 . Briefly, the catheter has a short monorail tip design and is delivered over a 0.014-inch floppy radiopaque wire. The catheter device contains a custom-drawn doubleclad fiber that has a single mode core that transmits 1310 nm wavelength OCT light, and a multimode inner cladding that transmits NIRF excitation light at 750 nm, and receives emitted fluorescence light from 765-855 nm. The double-clad fiber is enclosed by a wound cable driveshaft, and the fiber-driveshaft assembly is contained within a 2.4 French (F) outer transparent sheath. The distal end of the fiber is attached to a side-viewing ball-lens, designed to partially compensate optical aberrations caused by the transparent sheath, providing focused, co-registered OCT and NIRF excitation spots within the artery wall 6 .
Intravascular NIRF-OCT molecular-structural imaging in vivo
Rabbits underwent NIRF-OCT imaging at day 7 or day 28 after stent implantation (Supplemental Figure 1) . Two hours after intravenous injection of FTP11-CyAm7 (50 nmol/kg), rabbits were anesthetized and administered heparin/nitroglycerin as above. Rabbits then underwent insertion of a 5F sheath into a carotid artery and a 4F sheath into an iliac artery. The NIRF-OCT catheter was advanced retrograde to the abdominal aorta via the iliac artery. To optimize blood clearance during OCT imaging, a 6.0 mm balloon (Armada 35, Abbott Vascular) was also advanced from the carotid artery to the bifurcation of renal artery. After the additional nitroglycerin administration, image acquisition was performed. During the pullback (2.5-10 mm/second) of the NIRF-OCT catheter, blood flow was occluded by inflating the 6.0 mm balloon to nominal pressure, and then saline was flushed via the balloon lumen during balloon inflation (Supplemental Figure 2) . After the final NIRF-OCT in vivo study, animals were euthanized. The stented vessels were carefully resected and rinsed with normal saline for ex vivo imaging and histological analyses.
Ex vivo imaging and histology
Excised vessels were examined with a fluorescence reflectance imaging (FRI) system (Kodak Image Station 4000MMPro, Carestream Health Inc.) and with an epifluorescence microscope (Nikon Eclipse 90i, Japan). Resected vessels were next fixed with 4% PFA overnight at 4°C, and then underwent electrochemical stent dissolution 7 . Briefly, metallic stents were dissolved in a plastic container filled with 5% citric acid by electrolysis. An electrical wire connected each stent to a power supply. After dissolution, residual stent strut fragments were carefully removed with fine tweezers. Then the residual aortic wall was embedded in optimal cutting temperature (OCT) compound (Sakura Finetek, Torrance, CA). Serial 6-μm cryostat sections were obtained for histological analysis. Obtained sections were stained with hematoxylin and eosin (H&E) for general morphology and Carstairs' staining to visualize fibrin deposition. Histological sections and in vivo axial images were matched by the distance from the stent edges.
For en face epifluorescence microscopy (Nikon 90i), a subset of stented vessels from day 7 animals were cut longitudinally without electrochemical stent dissolution, allowing direct comparison between in vivo 2D NIRF images and ex vivo NIR epifluorescence microscopy images. Stent fragments were then gently removed with fine tweezers. Immunostaining of fibrin was also performed (Sekisui Diagnostics, Lexington MA) 8 . Fluorescence microscopy was performed on stained whole-mount tissue using an upright epifluorescence microscope (Nikon Eclipse 90i, Tokyo, Japan). Fluorescence images were obtained in the NIR channel for FTP11 (excitation/emission; 710/810 nm), UV channel for DAPI (350/460 nm), and FITC channel for autofluorescence (480/535 nm). In vivo OCT-NIRF axial images were co-registered to ex vivo axial fluorescence microscopy images along the longitudinal z-axis of the stent based on the stent edges defined by the 12mm stent length. Minimal vessel shortening was observed ex vivo (e.g. Figure 1A ) which facilitated co-registration. Angular co-registration of in vivo and FM axial images was performed visually if fiducials such as side branches were not present.
Subsets of day 28 stented tissues were shipped to CBSET (Lexington, MA) to perform traditional histological processing of stented tissues followed by dehydration in a graded series of ethanol and embedded in methylmethacrylate (MMA) plastic. Sections were then cut on a rotary microtome at 4 to 6 μm.
Image analysis
Simultaneously acquired OCT and NIRF data were processed using MATLAB (2013a, MathWorks, Natick, MA) as previously described 9 .
NIRF fibrin signal analysis. The FTP11 NIRF fibrin signal was distance-corrected using the catheter position derived from the OCT images. 6, 9 After the distance compensation, the mean NIRF signal intensity was measured in each at 400 μm intervals across the stent (30 slices per 12 mm stent). The mean NIRF signal intensity was then divided by the mean intensity of the uninjured remote aorta to calculate a target-to-background ratio (TBR). The fibrin NIRF signal intensity was evaluated in quartiles across each stent (proximal edge, mid-proximal, mid-distal, and distal edge).
OCT stent analysis. Axial OCT cross-sectional images were analyzed at 400 μm intervals matched to the above NIRF slices. Stents struts were classified as covered if tissue was visible over the stent strut. If a stent strut was not covered, it was classified as uncovered 10 . Peri-strut low-intensity area (PLIA) was defined and measured as previously reported 11 .
OCT stent strut coverage by NIRF fibrin-positive tissue. We defined an OCTcovered stent strut as fibrin-rich if the NIRF stent strut signal had a TBR of > 1.3. The percent of NIRF fibrin-rich covered stent struts at the stent edges (2 mm on each side, 10 images per stent) was calculated by the dividing number of NIRF fibrin-rich struts by the total number of struts deemed covered by OCT.
OCT tissue coverage of stent strut signal analysis. The grayscale intensity of stent strut coverage in OCT was analyzed by normalizing the stent strut signal as previously reported 12 , and compared between BMS and DES. Matched histological sections from the NIRF-OCT images were selected according to the longitudinal distance from the stent edges and the anatomical fiducials 13, 14 .
Statistical Analysis
Results are expressed as mean±SD. Statistical comparisons among multiple groups were evaluated by the Kruskal-Wallis test for multiple groups followed by the Dunn's post-test. For comparison between two groups within the same animal (day 7 vs. day 28 BMS, day 7 BMS vs. DES, and serial imaging at d7 vs. d28), the Wilcoxon matched pairs signed rank test was used and compared in each slice (30 slices per stent). The %coverage and %malapposition analyses were calculated per stent and compared between BMS and DES at each timepoint by Mann-Whitney test. OCT grayscale assessment was performed at stent edges (2 mm of each stent side = 5 slices of each edge) and compared by Kruskal-Wallis test followed by the Dunn's post-test. Statistical comparisons and half-life calculations were performed with GraphPad Prism Software (La Jolla, CA). Two-side p-values are reported. A value of P<0.05 was considered statistically significant for two and multiple groups comparison. Twosided p-values are reported. For multiple testing, adjusted p-values are reported.
Supplemental Results
We assessed the relation between peri-strut low-intensity area (PLIA) and fibrin deposition. OCT PLIA may serve as a possible marker of abnormal healing by representing hyaluronic acid and proteoglycan replacement of fibrin 11, 15, 16 , but has not been extensively studied. At day 28, PLIA analysis of 864 stent strtus revealed that PLIA did not correlate with the NIRF-fibrin signal (r=0.07, p=NS) at day 28; however, PLIA correlated weakly with the NIRF fibrin signal at day 7 (r=0.14, p<0.05, Supplemental Figure 7 ). Histological evaluation revealed that PLIA+ areas showed less collagen and fibrin deposition. The overall findings suggest that presence of PLIA does not depict current fibrin deposition, but may represent prior fibrin deposition, compatible with past reports 11, 15, 16 .
We further identified several images of interest during this study, including mural thrombosis, a dislodged stent, and an overlapped, malapposed stent. These images are shown in Supplemental Figure 8 . Figure S1 Supplemental Figure 1 . Experimental design of in vivo studies. (A) To image both day 7 and day 28 BMS within the aorta of a single rabbit, BMS were implanted at 28 days and 7 days prior to imaging. (B) To compare fibrin deposition and dissipation between BMS and EES, stents were implanted without overlap. NIRF-OCT imaging was performed at day 7, followed by second imaging session at day 28. Subsets of rabbits were imaged and sacrificed at day 7.
Supplemental Figures
Figure S2
Supplemental Figure 2 . NIRF-OCT imaging in rabbits. Imaging apparatus of NIRF-OCT pullback in a rabbit is shown. The NIRF-OCT catheter was introduced via the iliac artery and advanced retrograde into the infrarenal aorta. Pullback of the catheter was performed using saline flushing and proximal blood occlusion via a 6.0mm occlusion balloon advanced antegrade to a level just below the renal arteries. Representative in vivo axial NIRF-OCT images of (E) d7 BMS, (F) d28 BMS, and (G-H) Carstairs' stain. Edge stent struts of d7 BMS were covered by fibrin. In contrast d28 BMS struts exhibited minimal fibrin-positive NIRF signal in the healed neointima. (I) Fibrin content (TBR of NIRF signal) across the length of d7 and d28 BMS. TBR=target-to-background ratio. Scale bar=1mm. Supplemental Figure 7 . NIRF-OCT fibrin deposition at day 7 is associated with the development of peri-strut low-intensity areas (PLIA) at OCT follow-up at day 28 in rabbits. (A) The yellow arrows indicate the struts with elevated NIRF signal at day 7 in a BMS. The red arrows indicate struts with lower NIRF signal at day 7. (B) Struts that exhibited higher NIRF fibrin signal at day 7 (yellow arrows in A) developed PLIA at day 28 follow-up OCT. Magnified NIRF-OCT and corresponding histological images of PLIA-positive area (D-F, from solid box in B). In contrast, PLIA-negative areas at day 28 (G-I, from dotted box in B) demonstrated low NIRF-fibrin signal at earlier day 7 NIRF imaging (red arrows in B). Minimal fibrin deposition was evident on the day 28 follow-up Carstairs' stain or fibrin immunostain. PLIA=peri-strut low intensity area. 
